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21941-590 Rio de Janeiro, RJ, Brazil
2
Departamento de Pediatria, Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira,
FIOCRUZ, 22250-020 Rio de Janeiro, RJ, Brazil
Correspondence should be addressed to Pedro Xavier-Elsas; pxelsas@yahoo.com.br
Received 19 January 2015; Revised 27 March 2015; Accepted 1 April 2015
Academic Editor: Alex Kleinjan
Copyright © 2015 Pedro Xavier-Elsas et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Exogenously administered glucocorticoids enhance eosinophil and neutrophil granulocyte production from murine bone-marrow.
A hematological response dependent on endogenous glucocorticoids underlies bone-marrow eosinophilia induced by trauma or
allergic sensitization/challenge. We detected a defect in granulopoiesis in nonsensitized, perforin-deficient mice. In steady-state
conditions, perforin- (Pfp-) deficient mice showed significantly decreased bone-marrow and blood eosinophil and neutrophil
counts, and colony formation in response to GM-CSF, relative to wild-type controls of comparable age and/or weight. By contrast,
peripheral blood or spleen total cell and lymphocyte numbers were not affected by perforin deficiency. Dexamethasone enhanced
colony formation by GM-CSF-stimulated progenitors from wild-type controls, but not Pfp mice. Dexamethasone injection
increased bone-marrow eosinophil and neutrophil counts in wild-type controls, but not Pfp mice. Because perforin is expressed in
effector lymphocytes, we examined whether this defect would be corrected by transferring wild-type lymphocytes into perforindeficient recipients. Short-term reconstitution of the response to dexamethasone was separately achieved for eosinophils and
neutrophils by transfer of distinct populations of splenic lymphocytes from nonsensitized wild-type donors. Transfer of the same
amount of splenic lymphocytes from perforin-deficient donors was ineffective. This demonstrates that the perforin-dependent,
granulopoietic response to dexamethasone can be restored by transfer of innate lymphocyte subpopulations.

1. Introduction
Glucocorticoids have been extensively characterized as being
anti-inflammatory [1] and/or immunosuppressive [2] in therapeutic settings and are generally discussed as opposed to the
development of inflammation and limiting of production or
maturation of some effector immune cell types, in a physiological context [3]. Nevertheless, there is a well-established
association between stress and allergic diseases, including

asthma [4, 5]. Glucocorticoids, which are an essential part of
systemic stress responses, play coadjuvant roles in promoting
inflammation and may promote Th2-type immunity through
differential effects on Th1 × Th2 cytokine production [5, 6].
Chronically stimulated eosinophil production (eosinopoiesis) is an important feature of human asthma [7] and of
murine allergic asthma models [8]. In both cases, allergen
challenge of sensitized subjects increases eosinopoiesis in
the bone-marrow [7, 8]. This effect is antigen-specific and
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can be abolished by inducing oral tolerance to the allergen,
which affects both eosinophils and neutrophils in bonemarrow [9]. The effects of oral tolerization in bone-marrow
neutrophil and eosinophil granulocytes can be duplicated by
transfer of splenic T lymphocyte subpopulations from tolerized/sensitized/challenged donors to histocompatible naive
recipients [9]. These observations highlight the importance
of acquired cellular immunity in regulating the hematological
response to allergen sensitization and challenge. They further
suggest the possibility that granulopoiesis, encompassing
both eosinophil and neutrophil production, might be regulated by lymphocyte populations in nonsensitized subjects as
well.
In an allergic asthma model, we demonstrated a critical
role for endogenous glucocorticoids in the hematological
response to allergen challenge: challenge induces a corticosterone surge that is paralleled by increased eosinophilia
of bone-marrow in vivo and by increased responsiveness to
IL-5, the major eosinopoietic cytokine, ex vivo; the bonemarrow response to challenge is abolished by blockade of
glucocorticoid signaling or glucocorticoid production [10].
On the other hand, in the absence of allergen sensitization
and challenge, we have also obtained evidence of a link
between the corticosterone surge induced by mild surgical
trauma and short-term bone-marrow eosinophilia; again,
blockade of endogenous glucocorticoid production or action
abolished the bone-marrow eosinophilia induced by trauma
[11]. These in vivo effects of corticosterone, an endogenous
glucocorticoid released by the adrenal glands [10], are paralleled by those of exogenously provided corticosterone or
dexamethasone on murine bone-marrow [12, 13] and of other
glucocorticoids on human hemopoietic cells [14]. In BALB/c
mice, dexamethasone increases eosinophil production in
murine bone-marrow culture [12, 13] and primes bonemarrow cells in vivo for increased ex vivo responses to IL5 [12]. During further screening of inbred mouse strains
for differences in the granulopoietic responses to dexamethasone, we observed bone-marrow eosinophilia in mice of
the C57BL/6 (B6) background injected with dexamethasone,
which was undetectable in perforin-deficient B6 mutants [15]
submitted to the same treatment.
Perforin is a major mediator of cellular immunity [15–
19], expressed in lymphocyte populations which fight viral
[15] and bacterial pathogens [16, 17] as well as malignant
cells [18] in the context of both innate and acquired immune
responses. Perforin is also expressed by murine bone-marrow
neutrophils, which have a critical regulatory role in T cellmediated contact hypersensitivity [19]. Perforin deficiency is
known to induce complex changes in leukocyte populations
in humans and mice [16, 17, 20], including a classical presentation of familial hemophagocytic lymphohistiocytosis,
characterized by early life onset, high mortality, and multiple
immunological defects, including uncontrolled activation
and proliferation of CD4+ and CD8+ T cells, cytokine storm,
macrophage activation and proliferation, pancytopenia, and
anemia [20]. Here we report that perforin deficiency also
presents a selective defect in granulocyte production, which
can be corrected by wild-type lymphocyte transfer.
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2. Methods
2.1. Reagents. Fetal bovine serum (cat. SH30088.03),
RPMI1640 (SH30011.01), and IMDM (SH30228.01) were from
Hyclone (Logan, UT, EUA); L-glutamine (G7513), penicillinstreptomycin solution (P4333), essential amino acids solution
(50x) (M5550), methylcellulose (M0387), dexamethasone
(21-phosphate, disodium salt, D1159), Mifepristone (RU486,
M8046), and Histopaque-1083 (10831) were from SigmaAldrich Corporation (St. Louis, MO, EUA); Agar Noble
(0142-15/21422) was from Difco (Detroit, MI, EUA); nonessential amino acids solution (100x), (11140-050) and MEM
vitamin solution (100x) (11120-052) were from GIBCO Life
Technologies (Carlsbad, CA, USA); recombinant murine
IL-5 (405-ML-025) was from R&D Systems (Minneapolis,
MN, USA); recombinant murine GM-CSF (315-03) was from
PreproTech (Rocky Hill, NJ, USA); rat antimouse CD8b
(Clone: eBioH35-17.2, 12-0083-82, 0.2 mg/mL) was from
eBioscience (San Diego, CA, USA); magnetic microspheres
conjugated to antimouse CD4 (L3T4, 130-049-20) and to
goat antirat IgG (130-048-501, as secondary antibody to
primary rat antimouse CD8b) were from Miltenyi Biotec
(Ambriex, SP, Brazil).
2.2. Animals and Ethical Aspects. Wild-type C57BL/6, perforin-deficient (Pfp) mutants of the B6 background, and wildtype B6.129 mice were bred by CECAL-FIOCRUZ, Rio de
Janeiro, Brazil. The Pfp stock was derived from the original
B6.129S6-Pfptm1Clrk stock [15] by backcrossing to C57BL/6
at FIOCRUZ. Unless otherwise indicated, the wild-type
controls for the experiments shown were C57BL/6; in selected
experiments, B6.129 wild-type controls were used and yielded
the same results as C57BL/6 (not shown). The animals
were housed and handled following institutionally approved
guidelines under License L-00209 from CEUA-FIOCRUZ.
Euthanasia was by CO2 narcosis. For age and weight of the
animals, see Section 3. Routinely, female mice were used for
the experiments, since male mice characteristically fight for
dominance in the same cage, and the stress associated with
fighting may confound the interpretation of the results. We
have no evidence, however, that the granulopoietic responses
described here, including the strain differences, are restricted
to females.
2.3. In Vivo and Ex Vivo Procedures. Dexamethasone in saline
solution was injected i.p. (200 𝜇L, i.p., amounting to 5 mg/kg;
[12]). Controls received saline only. All sample collection was
done 24 h later. Where indicated, RU486 in 0.1% methylcellulose was given intragastrically 2 h before dexamethasone
with a gavage needle (200 𝜇L, amounting to 100 mg/kg [21]).
For lymphocyte transfers, 107 nylon-wool purified cells [22]
from naive C57BL/6 donors in a 100 𝜇L volume of sterile
saline were injected into the tail vein of Pfp recipients, once.
Controls received an equal number of cells from Pfp donors.
Where lymphocytes depleted of CD4+ or CD8+ cells were
used, the amount of cells injected was that recovered from
107 initial unseparated lymphocytes, in 100 𝜇L sterile saline,
i.v. Dexamethasone was administered to the recipients, in
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both cases, 48 h after lymphocyte transfer. Samples were
therefore collected 72 h after transfer. Where indicated, bonemarrow, peripheral blood from the abdominal vena cava,
spleens, and whole thymuses were collected, for enumeration
of cells or determination of relative weight of the thymus
(mg/g body weight) [21, 23]. Bone-marrow collected from
both femurs of each mouse in 5 mL RPMI1640 medium/1%
FBS with a 22-gauge needle and kept on ice was used for
total and differential counts and cell culture (see below).
Spleen mononuclear cells were the source for isolation of
lymphocytes (see below) [24, 25].
2.4. Bone-Marrow Methods. Total cells diluted in Turk’s
solution were counted in a haemocytometer. Differential
counts were carried out in cytocentrifugates after fixation
in PBS-10% formaldehyde and staining for eosinophil peroxidase (EPO [26, 27]) followed by counterstaining with
Harris’ hematoxylin [8]. EPO is a lineage-selective marker
detectable at all stages of eosinophil differentiation [27].
Liquid bone-marrow cultures were established at 37∘ C, with
106 bone-marrow cells in 1 mL RPMI1640/10% FBS, in 5%
CO2/95% air, plated in 24-well plates (cat. N∘ : 142475, NUNC
Brand Products) with IL-5 (1 ng/mL; 7 days [8]). Where
indicated, dexamethasone was added (10 𝜇L/well, to 10−7 M
final concentration [12]). Cytocentrifugates were prepared
after collection of the cultures and stained for EPO. Absolute
numbers were calculated from total cell counts in Turk’s
solution multiplied by the % of EPO+ cells (eosinophillineage cells, both mature and immature) in cytocentrifuge
smears. Triplicate semisolid (clonal) bone-marrow cultures
were established for 7 days with 2×105 cells adjusted to 1 mL of
1 : 1 IMDM/agar mix, in 35 mm tissue culture plates (Nunc), in
the presence of GM-CSF (2 ng/mL final [12]), with or without
dexamethasone (10−7 M), at final 20% FBS and 0.3% agar
concentrations. Total colonies (defined as aggregates >50 cells
derived from a single progenitor cell) [8, 12] were scored at
day 7 under an inverted microscope (400x, phase contrast).
2.5. Lymphoid Cell Methods. For lymphocyte isolation,
spleens were collected and minced in RPMI1640/1% FBS on
tissue culture plates. Spleen mononuclear cells (2 × 107 in
10 mL RPMI1640/1% SFB) were isolated by centrifugation
on a 1.083-density Ficoll-Hypaque cushion (3 mL, at 400 ×g,
for 30 minutes, at room temperature, following manufacturer’s instructions) [24, 25]. Cells recovered from the
medium/Ficoll-Hypaque interface were collected, washed in
serum-free medium, resuspended, counted, and further separated on nylon-wool columns [24, 25] at 4 × 108 cells/2 mL/g
nylon wool [24]. Cells eluted in a total 25 mL warm medium,
dropwise, were washed and counted before cytocentrifugation/staining or incubation with antibodies. Negative selection [24] was done with MidiMACS immunomagnetic separation device (cat. 130-042-302, Miltenyi Biotec) using LS+
MACS (cat. 130-042-401) columns. Depletion of CD4+ cells
was done with 10 𝜇L L3T4/107 nylon-wool purified lymphocytes in 100 𝜇L serum-free RPMI1640, on ice, following
manufacturers’ instructions. Depletion of CD8+ cells was in
two steps, with rat antimouse CD8b conjugated with PE,
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followed by goat antirat IgG (20 𝜇L/107 lymphocytes in 80 𝜇L
medium, on ice). Columns were eluted with 9 mL medium,
dropwise, over a 5-minute period. The depleted lymphocyte
populations were pelleted and resuspended for transfer like
the unseparated lymphocytes.
2.6. Statistical Procedures. Data are presented as Mean +
SEM. The numbers of experiments (𝑛) are indicated in the
caption of the figures, to avoid overcharging the figures and
captions. For comparisons of two groups (Figures 1 and 2), we
used the two-tailed 𝑡-test with separate variances (Systat for
Windows, version 5, Systat Inc., Evanston, IL). For multiple
comparisons (Figures 3, 4, 5, and 6), we used ANOVA, with
the Tukey HSD correction for groups of equal size (Systat
for Windows) or with Bonferroni’s correction for groups of
unequal size (using Prisma 5 for Windows, Graph Pad, La
Jolla, CA), unless otherwise indicated in Section 3.

3. Results
3.1. Evidence for a Defect in Steady-State Granulopoiesis in
Perforin-Deficient Mice. Following preliminary experiments
(not shown) that evidenced a positive response to dexamethasone in B6 wild-type mice, as well as the absence of
any response, positive or negative, in Pfp mutants of the B6
background, we reviewed data on freshly harvested bonemarrow from a large number of mice of both strains (𝑛 = 44
and 𝑛 = 48, resp.), to look for evidence of strain differences
in bone-marrow steady-state parameters, in the absence of
dexamethasone exposure (Figure 1).
A significant difference was observed in this large series,
with Pfp mice having lower bone-marrow cellularity than
wild-type controls (Figure 1(a); 𝑝 < 0.001). The data available
for EPO+ cells (Figure 1(b); 𝑝 = 0.033) and neutrophils
(Figure 1(c); 𝑝 = 0.010) of the mice in the large series
showed significant differences as well, with lower counts in
Pfp mutants. As the two groups were defined only on the
basis of genetic differences (presence or absence of functional
perforin genes), these differences could still be accounted for,
in principle, by variance due to nongenetic factors within
these groups, especially those which influence growth and
development. Because bone-marrow cellularity is roughly
proportional to the size of the animal, we next evaluated
whether these differences would disappear in the comparison
between groups of control and mutant mice matched by
weight (Figures 1(d)–1(f)). Significant differences were still
observed for total cells (Figure 1(d); 𝑝 = 0.001), eosinophils
(Figure 1(e); 𝑝 = 0.004), and neutrophils (Figure 1(f); 𝑝 =
0.011), all three parameters being lower in the mutant mice.
Because age might affect bone-marrow function through
mechanisms unrelated to body weight gain (as senescence
may have an earlier onset in some strains; furthermore, age
is a major determinant of incidence of many pathological
processes, such as malignancies), we next examined whether
matching by age (all animals at 12 weeks) would eliminate
the differences. Significant differences were still found for all
three parameters (for Figures 1(g)–1(i), resp., 𝑝 = 0.001, 𝑝 =
0.006, 𝑝 = 0.001), which were lower in the mutant mice. Even
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Figure 1: Total and granulocyte counts in freshly harvested bone-marrow of Pfp mice and B6 wild-type controls. Data are Mean + SEM of
the counts of total nucleated cells ((a), (d), (g), (j)), EPO+ cells ((b), (e), (h), (k)), and neutrophils ((c), (f), (i), (l)) in C57BL/6 (white bars) and
perforin-deficient (Pfp, black bars) bone-marrow. (a)–(c) No matching of age or weight between mutant and control groups; (d)–(f) groups
matched by weight (median = 21 g, range 19 g–23 g); (g)–(i) groups matched by age (all at 12 weeks); (j)–(l) groups matched by weight and
age. For B6 and Pfp mice, respectively, in (a), 𝑛 = 44 and 𝑛 = 48; in (b), 𝑛 = 27 and 𝑛 = 30; in (c), 𝑛 = 27 and 𝑛 = 24; in (d) and (e), 𝑛 = 6
for both; in (f), 𝑛 = 5 and 𝑛 = 6; in (g), (h), and (i), 𝑛 = 7 for both. In (j), (k), and (l), 𝑛 = 3 for both. ∗ Significant differences between the
indicated groups.

matching by both weight and age (for Figures 1(j)–1(l), resp.,
𝑝 = 0.022, 𝑝 = 0.032, 𝑝 = 0.001) failed to eliminate these
significant differences between controls and mutants for any
of the three parameters, which were all lower in the mutant
mice. Overall, this suggests that bone-marrow cellularity, as
well as bone-marrow eosinophil and neutrophil counts, is
significantly lower in Pfp mutants than in B6 mice and that
this difference cannot be dismissed as created by undue comparisons of two groups differing in body weight, age, or both.
We further examined (Figure 2) the counts of total
cells, lymphocytes, neutrophils, and eosinophils in peripheral
blood of weight-matched (median 21 g, range 19–23 g) B6
and Pfp mice. Unlike bone-marrow, peripheral blood total
nucleated cell counts did not differ significantly between
these strains (Figure 2(a), 𝑝 = 0.795), nor did lymphocyte
counts (Figure 2(b), 𝑝 = 0.417). By contrast, both neutrophil
(Figure 2(c), 𝑝 = 0.025) and eosinophil (Figure 2(d); 𝑝 =
0.030) counts were significantly different, and, like in bonemarrow, lower in Pfp mice. Together, the data in Figures 1
and 2 suggest that, even in the absence of dexamethasone,
Pfp mice have reduced granulocyte numbers both inside
and outside of bone-marrow, relative to wild-type controls of
comparable body weight.
3.2. In Vitro Response to Dexamethasone in B6 and Pfp BoneMarrow. Our original observation of this strain difference
was increased % eosinophils in cultured bone-marrow from
B6, but not Pfp, mice when both IL-5 and dexamethasone
were present (Jones and Cardoso de Mendonça, unpublished
observations). This is, however, insufficient to characterize
a strain difference in response to dexamethasone, because

the % of a given cell type in a bone-marrow sample, which
has a highly heterogeneous composition, can be increased
artifactually by a corresponding decrease in another cell
type, rather than by a positive effect of dexamethasone on
the cell type of interest. To confirm a positive effect of
IL-5 and dexamethasone in stimulation of wild-type and
mutant eosinopoiesis, liquid cultures were established from
the same number of bone-marrow cells (106 ) from B6 or
Pfp donors, in the presence of IL-5, alone or associated with
dexamethasone, and the absolute numbers of eosinophils
in the culture were determined. As shown in Figure 3, eosinophils were produced in cultures of IL-5-stimulated wildtype and mutant bone-marrow (Figure 3(a)). Control cultures lacking IL-5 do not contain eosinophils at the end
of the culture period (not shown; [8]). Counts of EPO+
cells recovered at the end of the culture were increased in
the presence of dexamethasone (10−7 M), relative to IL-5
controls, in cultures from B6 controls, but not from Pfp
mutants (Figure 3(a), 𝑝 < 0.001). Nevertheless, the IL-5
present was sufficient to sustain eosinopoiesis in the absence
of dexamethasone by Pfp bone-marrow to the same level
observed in B6 control cultures. On the other hand, data
from semisolid cultures, which allowed us to examine the
effects of dexamethasone on several classes of progenitors
(colony-forming cells), including the granulocyte (G) and
granulocyte-macrophage (GM) progenitors, which produce
neutrophils, are also shown in Figure 3. The total counts of
colonies formed by GM-CSF-stimulated Pfp bone-marrow
progenitors, in the absence of dexamethasone, also differed
significantly from those of B6 controls (𝑝 ≤ 0.001): even
though identical numbers of bone-marrow cells were plated,
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Figure 2: Total leukocyte, lymphocyte, and granulocyte counts in peripheral blood of Pfp mice and B6 wild-type controls. Data are Mean +
SEM of total leukocyte (a), lymphocyte (b), neutrophil (c), and eosinophil (d) in 1 mL of peripheral blood of B6 (white bars) and Pfp (black
bars) matched by weight (median = 21 g, range 19 g–23 g; 𝑛 = 6 for both). ∗ Significant difference between the indicated groups.

less colonies were made by perforin-deficient bone-marrow
(Figure 3(b)). Furthermore, dexamethasone (10−7 M) significantly stimulated colony formation by B6 bone-marrow (𝑝 =
0.002) but failed to stimulate (𝑝 = 0.558) Pfp bone-marrow
in the same conditions (Figure 3(b)). These observations
show that bone-marrow progenitors from Pfp mice differ
significantly from those of B6 controls, because they form less

colonies and do not respond to dexamethasone, which significantly enhances colony formation in the wild-type cultures.
3.3. In Vivo Bone-Marrow Response to Dexamethasone in Control and Perforin-Deficient Bone-Marrow. We next examined
the effect of dexamethasone (5 mg/kg injection [12]) on bonemarrow eosinophils and neutrophils, as well as on the relative
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Figure 3: Effectiveness of dexamethasone on in vitro eosinopoiesis in B6 and Pfp bone-marrow cultures. (a) IL-5-induced eosinopoiesis in
liquid culture. Data are Mean + SEM of the number of EPO+ cells recovered from 7-day cultures established from B6 ((a), white bars) or Pfp
((a), black bars) in the presence of IL-5 (1 ng/mL). Dex, dexamethasone. Data were from 3 separate experiments, carried out in 3 different
days, each providing data from 3 B6 and 3 Pfp mice (𝑛 = 9 for both strains). (b) GM-CSF-stimulated colony formation in semisolid culture.
Data are Mean + SEM of colony counts in 7-day semisolid cultures from B6 (white bars) and Pfp (black bars) bone-marrow established in
the presence of GM-CSF (2 ng/mL), alone or in association with Dex (10−7 M). For cultures without (left) and with (right) Dex, data are,
respectively, from B6, 𝑛 = 14 and 𝑛 = 7; Pfp, 𝑛 = 12 and 𝑛 = 6. ∗ Significant difference between the indicated groups.

weight of the thymus, which is significantly reduced by
glucocorticoids [21]. As shown in Figure 4, dexamethasone
injection increased the numbers of bone-marrow eosinophils
(Figure 4(a), 𝑝 = 0.003) and neutrophils (Figure 4(b), 𝑝 =
0.019) in vivo, relative to saline-injected controls, in wild-type
B6 mice, but not in Pfp mice. The effect of dexamethasone on
eosinophil numbers in wild-type B6 mice was abolished by
RU486 pretreatment, while RU486 had no effect of its own in
the absence of dexamethasone, in either B6 or Pfp mice (not
shown). The relative weight of the thymus was significantly
different (𝑝 = 0.010) between body weight-matched Pfp
mice and wild-type controls, suggesting a decreased thymic
cellularity in mutant thymus, even without exogenous glucocorticoid administration (Figure 4(c)). Importantly, dexamethasone injection did reduce significantly the relative weight
of the thymus in both wild-type (𝑝 = 0.007) and mutant (𝑝 =
0.001) mice (Figure 4(c)). Again, the effect of dexamethasone
on the thymus was abolished in both cases by RU486
pretreatment (not shown). Together, these observations show
that Pfp bone-marrow is unresponsive to dexamethasone
stimulation in vivo, although dexamethasone significantly
increases eosinophil and neutrophil numbers in the bonemarrow of wild-type controls. They also show that lack of
responsiveness to dexamethasone in Pfp bone-marrow is not
due to a general lack of response to glucocorticoids, because
the thymus of Pfp mice responds to dexamethasone injection
as expected.
3.4. Correction of the Defective Response to Dexamethasone
in Pfp Mice by Wild-Type Lymphocyte Transfer. Because
perforin is mainly expressed in various effector/regulatory

lymphocyte subsets, it was important to test whether the
perforin-related defect in bone-marrow response to dexamethasone could be corrected by introducing B6 lymphocytes
in Pfp mice. We have done so with splenic lymphocytes
from naive B6 donors, because both the baseline granulopoiesis defect and the defective granulopoietic response
to dexamethasone were observed in the absence of allergic
sensitization. The number (107 ) of lymphocytes for transfer
into individual mice was defined on the basis of similar
reconstitution studies [23]. To define whether elimination of
a particular lymphocyte subpopulation defined by standard
surface markers (CD4/CD8) prevented reconstitution of
the dexamethasone response, 107 total lymphocytes purified
from spleen were submitted to alternative depletion protocols
with marker-specific microbeads, and the depleted cells in
the column effluent, corresponding to the number of cells
negative for the selection marker present in the original
lymphocyte sample, were injected.
As shown in Figure 5, Pfp recipients of wild-type lymphocytes (unseparated) show a significant in vivo response to
dexamethasone injection, by increased total cell (Figure 5(a);
𝑝 = 0.032, 𝑡-test), eosinophil (Figure 5(b); 𝑝 = 0.04),
and neutrophil (Figure 5(c); 𝑝 < 0.001) counts in the
bone-marrow, sharply contrasting with observations in Pfp
mice in the absence of wild-type cell transfer (compare
Figure 4). On the other hand, depletion of CD4+ or CD8+
cells in the wild-type lymphocyte preparation gave distinct
results in the reconstitution assay, depending on the granulocyte population examined: while depletion of either subset
abolished the ability of splenic lymphocytes to reconstitute
the eosinopoietic response to dexamethasone (Figure 5(b)),
depletion of CD4+ cells did not prevent reconstitution of
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Figure 4: In vivo granulopoietic response to dexamethasone injection in B6 and Pfp mice ((a), (b)). Data are Mean + SEM of the numbers
of EPO+ cells (a) and neutrophils (b) in freshly harvested bone-marrow of age-matched (12 weeks) B6 (white bars) or Pfp (black bars) mice,
24 h after i.p. injection of dexamethasone (Dex, 5 mg/kg) or saline. For B6 and Pfp mice, 𝑛 = 3 and 𝑛 = 5, respectively. (c) Data are Mean +
SEM of the relative weight of the thymus (mg/g body weight) from age-matched B6 (white bars) or Pfp (black bars) mice, 24 h after injection
of dexamethasone or saline as above. For B6 and Pfp mice, 𝑛 = 4 and 𝑛 = 5, respectively. ∗ Significant differences relative to the indicated
controls.

the neutropoietic response (Figure 5(c); 𝑝 = 0.013), while
depletion of CD8+ cells prevented reconstitution.
As a further control, we performed transfer of Pfp lymphocytes into Pfp recipients and obtained no reconstitution
of dexamethasone responses, judged by any of these three
parameters (Figure 6). In these controls, dexamethasone
reduced significantly the relative weight of the thymus, showing that dexamethasone was able to reach systemically active
levels even if bone-marrow showed no evidence of responding to it.
Overall, these observations suggest that lymphocytes
from the spleen of naive wild-type mice, but not Pfp mice, are
able to reconstitute in the short term the granulopoietic
responses to dexamethasone, but different cells may be involved in reconstitution of lineage-specific (eosinophilic versus neutrophilic) responses.

4. Discussion
This is, to our knowledge [15–20], the first description of
a selective defect in granulopoiesis associated with perforin
deficiency in mice and of its correction by the intravenous
transfer of wild-type lymphocytes. As such, it extends the
range of manifestations associated with perforin deficiency
and raises the issue of how perforin contributes to regulation
of granulocyte lineages in vivo. Because the wild-type lymphocyte populations interact with a drug (dexamethasone)
which initiates signaling through the RU486-inhibitable
glucocorticoid receptor, to stimulate in vivo eosinophil and
neutrophil production, these observations may be relevant to
processes in which bone-marrow is stimulated by immune
responses [9] or trauma [10] with involvement of the same
receptor and of endogenous glucocorticoids released by the
adrenal glands.
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Figure 5: Short-term reconstitution of responses to dexamethasone in Pfp mice by transfer of B6 splenic lymphocytes. Data are Mean + SEM
of the total nucleated cells (a), EPO+ cells (b), and neutrophils (c) in freshly harvested bone-marrow of Pfp mice which had received total
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Perforin is a well-characterized effector protein, mainly
(but not exclusively) expressed in lymphocytes which share
the ability to induce cell-mediated cytotoxicity [15–20]. Perforin deficiency was initially characterized by the loss of
important cytotoxic lymphocyte functions [15–20]. However, it was soon realized that perforin deficiency entails
other, more complex, functional consequences, leading to
the development of type II familial hemophagocytic lymphohistiocytosis [16, 17, 20], which shares pathophysiological
features with the macrophage activation syndrome, including
interferon- (IFN-) 𝛾 overproduction. Hence, perforin deficiency has broader consequences in addition to impairment
of cytotoxic lymphocyte function, and IFN-𝛾, alone or in
association with other “cytokine storm” components, may
transduce its effects on other leukocyte lineages.
One of the issues raised by our findings is whether the
lower granulocyte numbers in blood and bone-marrow of
Pfp mice are due to the progression of the murine equivalent
of the human familial hemophagocytic lymphohistiocytosis
[16, 17, 20, 28]. It should be noted that the human familial
hemophagocytic lymphohistiocytosis is a severe condition,
presenting early in life in most cases and associated with
important mortality [20, 28]. Also, phenotypically distinct
forms correspond to different mutations with perforin
expressed at lower levels and/or with altered properties, a
situation that is not applicable to the present study, which
employed perforin null mice [15]. The perforin-deficient mice
in the original Walsh et al. study (from which the mice used
in this study descend) were described as healthy for at least
5 months [15]. In our study, mice were certified SPF and
maintained in microisolator units [15], with no evidence of
mortality, stunting, or signs of infection during the entire
observation period of up to 3 months (12 weeks).
On the other hand, Pfp defect in response to dexamethasone could be corrected by transfer of as few as 107 lymphocytes 48 h before the stimulus. The prompt reconstitution of
this defect argues against the lack of dexamethasone response
in Pfp animals being caused by a chronic inflammatory
disease of the bone-marrow, such as familial hemophagocytic
lymphohistiocytosis, which in humans is challenging for
therapy [28]. Because correction was achieved by simple
transfer of lymphocytes from naive donors, we think it
is more likely that the transferred lymphocytes provided
something that was lacking in the recipient.
Neutrophils were reduced in bone-marrow and blood
of Pfp mice relative to B6 controls. Lymphocytes, however,
were not. This not only shows that the neutrophil deficiency
has peripheral expression but further argues against reduced
numbers in bone-marrow being due to an increased export
of neutrophils to the periphery. The evidence from colonyforming assays suggests, instead, that production is greatly
reduced in Pfp relative to B6 mice, as there were less
GM-CSF-responsive progenitors in an identical number of
bone-marrow cells. Reduced production would explain the
decrease in granulocyte counts both outside and inside of
bone-marrow. On the other hand, normal numbers of lymphocytes and total leukocyte counts show that the defect is
selective for granulocytes, which are not the major circulating
leukocyte subpopulation in mice, so that reduction in their

Mediators of Inflammation
numbers does not have a major impact on total circulating
leukocyte counts. Neutropenia is associated with increased
susceptibility to bacterial and fungal infection, provided it
is severe enough. This was not observed in our study, so
presumably the Pfp mice were capable of coping with the
microorganisms present in a rather clean environment (SPF
conditions, microisolator housing). It remains to be seen,
however, whether following a more severe infectious exposure, such as that associated with sepsis induction, Pfp mice
would prove more vulnerable to bacterial dissemination.
This will be addressed in future studies, since emergency
granulopoiesis, as opposed to baseline granulopoiesis, is
driven by GM-CSF and related hemopoietic cytokines [29].
The lack of appropriate response to GM-CSF, both in the
absence and in the presence of dexamethasone, would predict
that emergency granulopoiesis would be defective in Pfp
mice and might therefore negatively influence the outcome of
sepsis. The hypothalamus-pituitary-adrenal axis is activated
in sepsis [30], and therefore it is possible that emergency
granulopoiesis is driven by endogenous glucocorticoids, in
a way consistent with our observations. The prediction, in
this case, is that perforin would be required for normal
host response to bacterial sepsis through an effect on glucocorticoid-mediated signaling in the bone-marrow.
The ability of lymphocyte preparations to reconstitute
responses to dexamethasone was abolished by depletion of
CD4+ and/or CD8+ cells before transfer, depending on the
granulocyte population. For neutrophils, CD8+ alone seemed
to be required. By contrast, for eosinophils both CD4+
and CD8+ cells were indispensable. While this suggests
that different mechanisms are involved for eosinophils and
neutrophils, it certainly raises the issue of the lymphocyte
subpopulation involved. Since naive lymphocytes are sufficient, it is not likely that conventional T cells, CD4+ or
CD8+, are responsible, for they would not be activated in this
isolation protocol [24, 25, 31]. Conventional NK cells would
not be a strong candidate, since CD4+ or CD8+ lymphocyte
depletion would probably not eliminate them [32, 33]. Innate
lymphocytes other than conventional NK cells, however,
would be expected to be present in naive mouse spleens [32,
33]. Natural killer T cells, which include subsets expressing
CD4 and CD8, are found in significant numbers in B6 spleen,
present an activated memory phenotype without known
activating exposure, and exert multiple regulatory functions
through rapid secretion of large amounts of cytokines [32, 33],
might perhaps account for some of our observations.
Regardless of innate or adaptive lymphocyte population
involved, two questions which require further study are as follows: (a) is perforin the missing component that is brought by
the transferred lymphocytes? and (b) do these lymphocytes
act by homing to the recipients’ bone-marrow and interacting
locally with granulocyte progenitors/precursors? Both questions, however, require a more complex experimental design
and resources to allow us to detect and modify perforin
expression inside living lymphocytes, as well as monitor their
homing to the bone-marrow compartment. For this reason,
such experiments fall outside the scope of this paper, which
is limited to the demonstration of the defect and of its
correction.
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Finally, it should be noted that lymphocyte transfer
restored the short-term response to dexamethasone but did
not bring the baseline counts of eosinophils and neutrophils
to the same level of the B6 controls. This might be interpreted
as evidence that steady-state granulopoiesis and response to
dexamethasone are unrelated processes (i.e., their perforin
deficiency entails two distinct defects in granulopoiesis,
rather than one defect with distinct manifestations). We
do not support this interpretation, however, because the
duration of the experiment might be insufficient for an
effect of lymphocyte transfer alone on steady-state granulocyte numbers to become noticeable. It is also possible that
demonstration of a durable effect on steady-state granulocyte
numbers would require not only an extended observation
period but also an increased or repeated input of wild-type
lymphocytes and an interaction of exogenous lymphocytes
with endogenous adrenal glucocorticoids as well.
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